NUSSLOCH, Germany, August 7, 2014 /PRNewswire/ --
- Leica Biosystems announces a collaboration with Bristol-Myers
Squibb to develop companion diagnostic tests in support of targeted
therapeutics
- Leica Biosystems will develop fully automated tissue-based
companion diagnostic tests to run on the BOND™ automated advanced
staining systems
Leica Biosystems, today announced an agreement with
Bristol-Myers Squibb Company (NYSE: BMY) to collaborate on
developing companion diagnostics on the Leica BOND system for use
as an aid in selecting patients for treatment with certain
pharmaceuticals developed, or to be developed, by Bristol-Myers
Squibb. Other terms of the agreement were not disclosed.
"We are pleased to be working with Bristol-Myers Squibb, on
diagnostics for cancer and other therapies on the Leica BOND
platform," added Matthias Weber,
President of Leica Biosystems, MD. "This partnership is an example
of Leica's continued growth in Companion Diagnostics. In this field
the capabilities to supply high quality In Vitro Diagnostic
products are critical requirements. The ease of use and high
staining quality of our BOND systems makes them ideal platforms on
which to deploy these very informative tests."
About Leica Biosystems
Leica Biosystems is a global leader in workflow solutions and
automation, striving to advance cancer diagnostics to improve
patients' lives. Leica Biosystems provides anatomic pathology
laboratories and researchers a comprehensive product range for each
step in the pathology process, from sample preparation and staining
to imaging and reporting. Leica's easy-to-use and reliable
offerings help improve workflow efficiency and diagnostic
confidence. The company is represented in over 100 countries. It
has manufacturing facilities in seven countries, sales and service
organizations in 19 countries, and an international network of
dealers. The company is headquartered in Nussloch, Germany. Further information can be found at
LeicaBiosystems.com.
SOURCE Leica Biosystems